Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hela Romdhani

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|November 4, 2019
Comparison of Time to Next Treatment, Health Care Resource Utilization, and Costs in Patients with Chronic Lymphocytic Leukemia Initiated on Front-line Ibrutinib or ChemoimmunotherapyBruno Emond, Murali Sundaram, Hela Romdhani, et al.
Genetic Epidemiology|January 6, 2015
Pathway-based association study of multiple candidate genes and multiple traits using structural equation modelsHela Romdhani, Heungsun Hwang, Gilles Paradis, et al.
Current Medical Research and Opinion|April 14, 2018
Economic burden of treatment failure in chronic lymphocytic leukemia patientsSong Wang, Marie-Hélène Lafeuille, Patrick Lefebvre, et al.
Journal of Drug Assessment|December 30, 2022
Treatment and comorbidity burden among people living with HIV: a review of systematic literature reviewsBabafemi O Taiwo, Hela Romdhani, Marie-Hélène Lafeuille, et al.
Pharmacoeconomics - Open|August 4, 2023
Disease Burden, Treatment Patterns, and Economic Impact of Rectovaginal Fistulas in Patients with Crohn's Disease: Findings from a Retrospective, Observational, Longitudinal Study Based on US Claims DatabasesChitra Karki, Dominick Latremouille-Viau, Inmaculada Gilaberte, et al.
Journal of Medical Economics|May 13, 2025
Non-optimal treatment with first tyrosine kinase inhibitor and associated economic burden in chronic myeloid leukemiaVamsi Kota, David Wei, Daisy Yang, et al.
Journal of Managed Care & Specialty Pharmacy|October 21, 2025
Burden of illness and unmet needs in patients with erythropoietic protoporphyria and X-linked protoporphyria: A large US nationwide claims analysisMaral DerSarkissian, Chelsea Norregaard, Hela Romdhani, et al.
Drugs - Real World Outcomes|February 10, 2021
Real-World Utilization and Safety of Daratumumab IV Rapid Infusions Administered in a Community Setting: A Retrospective Observational StudyLucio Gordan, Melody Chang, Marie-Hélène Lafeuille, et al.
Future Oncology (London, England)|April 7, 2025
Study of persistence and adherence to ADT in prostate cancer: relugolix, degarelix, and GnRH agonists in the USJason Hafron, Agnes Hong, Michael J Ryan, et al.
Pulmonary Therapy|May 17, 2026
Clinical Outcomes in Concurrent Cohorts of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA)-Treated versus ELX/TEZ/IVA-Ineligible Individuals with Cystic Fibrosis in the US during COVID-19Christian A Merlo, Hela Romdhani, Maral DerSarkissian, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Clinical Lymphoma, Myeloma & Leukemia|November 4, 2019
Comparison of Time to Next Treatment, Health Care Resource Utilization, and Costs in Patients with Chronic Lymphocytic Leukemia Initiated on Front-line Ibrutinib or ChemoimmunotherapyBruno Emond, Murali Sundaram, Hela Romdhani, et al.
Genetic Epidemiology|January 6, 2015
Pathway-based association study of multiple candidate genes and multiple traits using structural equation modelsHela Romdhani, Heungsun Hwang, Gilles Paradis, et al.
Current Medical Research and Opinion|April 14, 2018
Economic burden of treatment failure in chronic lymphocytic leukemia patientsSong Wang, Marie-Hélène Lafeuille, Patrick Lefebvre, et al.
Journal of Drug Assessment|December 30, 2022
Treatment and comorbidity burden among people living with HIV: a review of systematic literature reviewsBabafemi O Taiwo, Hela Romdhani, Marie-Hélène Lafeuille, et al.
Pharmacoeconomics - Open|August 4, 2023
Disease Burden, Treatment Patterns, and Economic Impact of Rectovaginal Fistulas in Patients with Crohn's Disease: Findings from a Retrospective, Observational, Longitudinal Study Based on US Claims DatabasesChitra Karki, Dominick Latremouille-Viau, Inmaculada Gilaberte, et al.
Journal of Medical Economics|May 13, 2025
Non-optimal treatment with first tyrosine kinase inhibitor and associated economic burden in chronic myeloid leukemiaVamsi Kota, David Wei, Daisy Yang, et al.
Journal of Managed Care & Specialty Pharmacy|October 21, 2025
Burden of illness and unmet needs in patients with erythropoietic protoporphyria and X-linked protoporphyria: A large US nationwide claims analysisMaral DerSarkissian, Chelsea Norregaard, Hela Romdhani, et al.
Drugs - Real World Outcomes|February 10, 2021
Real-World Utilization and Safety of Daratumumab IV Rapid Infusions Administered in a Community Setting: A Retrospective Observational StudyLucio Gordan, Melody Chang, Marie-Hélène Lafeuille, et al.
Future Oncology (London, England)|April 7, 2025
Study of persistence and adherence to ADT in prostate cancer: relugolix, degarelix, and GnRH agonists in the USJason Hafron, Agnes Hong, Michael J Ryan, et al.
Pulmonary Therapy|May 17, 2026
Clinical Outcomes in Concurrent Cohorts of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA)-Treated versus ELX/TEZ/IVA-Ineligible Individuals with Cystic Fibrosis in the US during COVID-19Christian A Merlo, Hela Romdhani, Maral DerSarkissian, et al.
Pageof 3